Five regions in the U.S. have been selected to implement a new preventive health initiative to improve care for people with a cluster of chronic conditions known as cardiovascular-kidney-metabolic ...
Bullish option flow detected in Novo Nordisk (NVO) with 21,940 calls trading, 1.5x expected, and implied vol increasing almost 3 points to ...
The Singapore International Commercial Court at the request of Novo Nordisk ordered the freezing of the worldwide assets of ...
Multiple system atrophy (MSA) is a rare neurological disorder that leads to the progressive deterioration of nerve cells in ...
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...
MarketBeat on MSN1d
Novo Nordisk Shares Near New 52-Week Low: Analysts See Big UpsideShares of weight loss and diabetes medication maker Novo Nordisk (NYSE: NVO) have slumped precipitously over the past 52 ...
Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...
Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
The increasing prevalence of kidney failure and end-stage renal disease, along with a growing incidence of risk factors like diabetes, hypertension, and aging, is driving the demand for artificial ...
DelveInsight's Artificial Kidney Market Insights report provides the current and forecast market analysis, individual leading ...
Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million– Following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback